In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

RXRX has reported updated data from its ELUCIDATE and TUPELO trials, but the stock has failed to mount a sustained rally. The ELUCIDATE update provides just an additional 10 patients of data treated ...

With a single click, unlock detailed, AI-assisted insights pulled from hundreds of financial data points instantly.

Learn how to improve coding assignments with clear documentation, better structure, and professional formatting for higher grades and clarity.